Skip to main content
Federal Circuit· 10/11/2007

Abbott Laboratories v. TorPharm, Inc.

Citations

  • 503 F.3d 1372
  • 84 U.S.P.Q. 2d (BNA) 1829
  • 2007 U.S. App. LEXIS 23803
  • 2007 WL 2948555

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

  • mentioning that the issuance of the injunction was appealed, but not linking this event to the court’s ability to enforce the clarity requirement
  • mentioning that the issuance of the injunction was appealed, but not linking this event to the court's ability to enforce the clarity requirement
  • “Requiring disputed issues to be tried through full litigation rather than summary proceedings eliminates due process concerns for the defendant accused of violating an injunction.”
  • allowing the use of expert testimony on the colorable differences question
  • allowing the use of expert testimony on the colorable differences question
  • noting the lack of “any authority, be it statute, case law, or legislative history of the Hatch-Waxman Act, suggesting that suits commenced under . . . the Act are to be treated any differently than patent infringement suits under 35 U.S.C. § 271(a).”

Source: CourtListener parenthetical corpus (CC0).

Judges: Michel, Chief Judge, Dyk, Circuit Judge, and Otero, District Judge

Read full opinion on CourtListener

Cited by

17 cases in this archive cite this case.

Cites

24 cases in this archive are cited by this case; the 20 most cited are listed.

Other cases named Abbott Laboratories v. TorPharm, Inc.

3 other CourtListener records share this case name.

Sourced from CourtListener / Free Law Project (CC0).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.